This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kende, M Articles by Canonico, P G Search for Related Content PubMed PubMed Citation Articles by Kende, M Articles by Canonico, P G

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 June; 27(6): 903-907

Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.

M Kende, C R Alving, W L Rill, G M Swartz Jr and P G Canonico

ABSTRACT

Administration of liposome-encapsulated ribavirin to mice led to ribavirin concentrations in the liver, the primary site of Rift Valley fever virus proliferation, that were fivefold greater than those attained with the same doses of free ribavirin. Liposomal ribavirin given at a dose of either 25 or 50 mg of drug per kg of body weight protected mice against a rapidly lethal high-titer challenge with Rift Valley fever virus, whereas similar doses of free drug or empty liposomes had no detectable benefit. Hence, tissue targeting of ribavirin with liposomes substantially increased the therapeutic index by increasing the efficacy of the treatment. By using liposomes as drug carriers, a nontoxic, low-dose regimen of ribavirin had a therapeutic effect that was comparable to that achieved with higher but potentially more toxic doses of free ribavirin.

---

Antimicrob Agents Chemother. 1985 June; 27(6): 903-907